A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
NCT ID: NCT01541423
Last Updated: 2021-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
83 participants
OBSERVATIONAL
2012-05-11
2016-09-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE
NCT00914966
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
NCT02052141
Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks
NCT01756157
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration
NCT01095497
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase
NCT01426763
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a diagnosis of HAE and be receiving CINRYZE for prevention or treatment of angioedema attacks
* Provide written informed consent/assent in compliance with applicable country-specific and local regulations
Exclusion Criteria
* Be receiving CINRYZE in an investigational study
* Be receiving another HAE therapy as part of a clinical trial
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shire
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitair Ziekenhuis Antwerpen (UZA)
Antwerp, Edegem, Belgium
Clinic St-Luc University Hospital
Brussels, , Belgium
CHU d'Angers
Angers, , France
Hôpital Claude-Huriez
Lille, , France
Immunologie Clinique et Allergologie
Nancy, , France
Hôpital Saint Antoine
Paris, , France
Université Paris Descartes
Paris, , France
Allergie-Centrum-Charite
Berlin, , Germany
Universitätsklinik Essen
Essen, , Germany
Johann Wolfgang Goethe Universität
Frankfurt, , Germany
Universität-Hautklinik Mainz
Mainz, , Germany
Hämophilie-Zentrum Rhein Main
Mörfelden-Walldorf, , Germany
Klinikum rechts der Isar der technischen Universität München
München, , Germany
Ospedale Luigi Sacco
Milan, , Italy
Azienda Ospedaliera "V. Cervello"
Palermo, , Italy
C.A.R San Pedro
Logroño, , Spain
Hospital General Universitario
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Barts and the London NHS Trust
London, , United Kingdom
Northern General Hospital
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain more information on the study, click here/on this link.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHP616-401
Identifier Type: -
Identifier Source: secondary_id
0624-401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.